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The potent M1 receptor allosteric agonist GSK1034702 improves episodic
memory in humans in the nicotine abstinence model of cognitive dysfunction
Abstract
Episodic memory deficits are a core feature of neurodegenerative disorders. Muscarinic M1 receptors
play a critical role in modulating learning and memory and are highly expressed in the hippocampus. We
examined the effect of GSK1034702, a potent M1 receptor allosteric agonist, on cognitive function, and in
particular episodic memory, in healthy smokers using the nicotine abstinence model of cognitive
dysfunction. The study utilized a randomized, double-blind, placebo-controlled, cross-over design in which
20 male nicotine abstained smokers were tested following single doses of placebo, 4 and 8 mg
GSK1034702. Compared to the baseline (nicotine on-state), nicotine abstinence showed statistical
significance in reducing immediate (p=0.019) and delayed (p=0.02) recall. GSK1034702 (8 mg)
significantly attenuated (i.e. improved) immediate recall (p=0.014) but not delayed recall. None of the
other cognitive domains was modulated by either nicotine abstinence or GSK1034702. These findings
suggest that stimulating M1 receptor mediated neurotransmission in humans with GSK1034702
improves memory encoding potentially by modulating hippocampal function. Hence, selective M1
receptor allosteric agonists may have therapeutic benefits in disorders of impaired learning including
Alzheimer's disease.
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ARTICLE
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Abstract
Episodic memory deﬁcits are a core feature of neurodegenerative disorders. Muscarinic M1 receptors play
a critical role in modulating learning and memory and are highly expressed in the hippocampus. We
examined the eﬀect of GSK1034702, a potent M1 receptor allosteric agonist, on cognitive function, and
in particular episodic memory, in healthy smokers using the nicotine abstinence model of cognitive
dysfunction. The study utilized a randomized, double-blind, placebo-controlled, cross-over design in
which 20 male nicotine abstained smokers were tested following single doses of placebo, 4 and 8 mg
GSK1034702. Compared to the baseline (nicotine on-state), nicotine abstinence showed statistical signiﬁcance in reducing immediate (p=0.019) and delayed (p=0.02) recall. GSK1034702 (8 mg) signiﬁcantly
attenuated (i.e. improved) immediate recall (p=0.014) but not delayed recall. None of the other cognitive
domains was modulated by either nicotine abstinence or GSK1034702. These ﬁndings suggest that
stimulating M1 receptor mediated neurotransmission in humans with GSK1034702 improves memory
encoding potentially by modulating hippocampal function. Hence, selective M1 receptor
allosteric agonists may have therapeutic beneﬁts in disorders of impaired learning including Alzheimer’s
disease.
Received 3 November 2011 ; Reviewed 19 December 2011 ; Revised 13 June 2012 ; Accepted 19 June 2012 ;
First published online 29 August 2012
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Introduction
Neurodegenerative disorders, including Alzheimer’s
disease (AD) and schizophrenia, are associated with
impairment across a range of cognitive domains,
although both disorders are characterized clinically
Address for correspondence : Professor P. J. Nathan, GSK Clinical
Unit Cambridge, Addenbrooke’s Centre for Clinical Investigations,
Cambridge Biomedical Campus, Cambridge CB2 2GG, UK.
Tel. : +44 1223 296081 Fax : +44 1223 296108
Email : pradeep.j.nathan@gsk.com

by substantial impairment in episodic memory. This
memory impairment underlies signiﬁcant diﬃculties
in activities of daily living including self-care and,
consequently, there is an urgent need for therapies to
improve memory in both AD and schizophrenia. In
both disorders, the impairment in episodic memory
reﬂects disruption to cholinergically modulated
neurocognitive networks for memory that centre on
the hippocampus (Hasselmo & Sarter, 2011) ; albeit
through diﬀerent disease speciﬁc pathological processes. Within these memory networks there is
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increasing evidence for impairment in muscarinic M1
receptors and their associated signalling pathways. In
AD, reductions in M1 or M1/M4 receptors have
been demonstrated in post-mortem autoradiography
(Rodrı́guez-Puertas et al. 1997) and single photon
emission computed tomography imaging (Pakrasi et al.
2007) studies. Although not all studies have been
consistent and some report a compensatory increase
in M1 receptors (Overk et al. 2010), M1 receptor signal
transduction-related markers or function are reportedly decreased or impaired in AD (Ferrari-DiLeo
et al. 1995 ; Potter et al. 2011 ; Tsang et al. 2006, 2007).
Similarly, several post-mortem [3H]pirenzepinebinding studies have demonstrated reductions in
M1/M4 receptors in speciﬁc brain regions, including
the hippocampus, in patients with schizophrenia
(Crook et al. 2000, 2001 ; Dean et al. 2002 ; Deng &
Huang, 2005). Hence, pharmacological modulation of
muscarinic M1 receptors may provide a therapeutic
opportunity for amelioration of episodic memory impairment in both disorders.
Within neurocognitive networks for memory, postsynaptic M1 receptors are predominantly expressed
throughout the cortex and hippocampus (Levey et al.
1991). Activation of M1 receptors increases ERK1/2
phosphorylation (Thiels & Klann, 2001), ampliﬁes
N-methyl-D-aspartate receptor mediated currents
(Marino et al. 1998) and hippocampal long-term
potentiation (LTP ; Buchanan et al. 2010 ; Fernández de
Sevilla et al. 2008), all of which are critical biochemical
and cellular mediators of learning and memory
(Malenka & Bear, 2004). Pre-clinical in vivo studies
using selective M1 receptor agonists have shown evidence for direct links between M1 receptor activation
and improved learning and memory (Brandeis et al.
1995 ; Fisher et al. 2002 ; Ruske & White, 1999 ; Vincent
& Sepinwall, 1992 ; Watt et al. 2011).
Despite their therapeutic potential, the magnitude of
beneﬁts to memory or cognitive function in humans
produced by muscarinic agonists has been modest and
often limited by peripheral M2 and/or M3 muscarinic
receptor-related side-eﬀects, such as severe gastrointestinal disturbance. The recent discovery that M1
receptors possess an allosteric (or ectopic) site that is
non-conserved across muscarinic acetylcholine receptor (mAChR) subtypes has provided the opportunity
to develop M1 receptor agonists with true receptor
selectivity (Spalding et al. 2002) and therefore of great
potential as memory enhancing agents in humans. In
animals, the selective M1 receptor allosteric agonist
AC-260584 has been shown to improve learning and
memory (Bradley et al. 2010 ; Vanover et al. 2008).
However, it is unknown if similar pro-cognitive eﬀects

can be observed in humans due to the paucity of
ligands available for probing muscarinic receptor subtypes, including the M1 receptor.
GSK1034702 is a selective M1 receptor allosteric
agonist, being developed for the treatment of cognitive
dysfunction in neurodegenerative disorders. It belongs to the series of novel N-substituted benzimidazolones recently described (Budzik et al. 2010 ; Huiban
et al. 2011). In vivo, an isomer of GSK1034702 (i.e.
compound 5 ; Budzik et al. 2010) enhanced cell ﬁring in
the CA1 region of the rat hippocampus and reversed
the scopolamine-induced amnesia in the hippocampus dependent passive avoidance task of learning in a
dose-related manner (Budzik et al. 2010). Using similar
methods, GSK1034702 caused a concentration dependent increase of hippocampal CA1 neuronal ﬁring
rate, which persisted following repeated treatment
(7 d) and reversed the scopolamine-induced amnesia
in the passive avoidance task following both acute and
sub-chronic (7 d at 6 mg/kg.d) treatment with challenge doses of 1, 3 or 10 mg/kg (see Supplementary
Material and Supplementary Figs. S1 and S2).
The aim of this study was to investigate, for the ﬁrst
time, the acute eﬀects of GSK1034702 on episodic
memory as well as more general aspects of cognitive
function in humans. The pro-cognitive eﬀects of
GSK1034702 were tested in healthy adult smokers who
had been abstinent from nicotine (i.e. nicotine abstinence model of cognitive impairment). We used the
nicotine abstinence model of cognitive impairment
because : (a) synergistic interactions between muscarinic and nicotinic receptors at both a molecular and
behavioural level have been reported (Ellis et al. 2006 ;
Greenwood et al. 2009) ; (b) nicotine abstinence (for at
least 12 h) in chronic smokers can reduce baseline
cognitive function, including memory, as previously
demonstrated (Myers et al. 2008).The primary hypothesis was that the M1 allosteric agonist GSK1034702
would attenuate the nicotine abstinence-induced
impairments in episodic memory. The eﬀects of
GSK1034702 on other aspects of cognitive function
shown to be relevant to AD and schizophrenia were
then investigated in exploratory analyses.
Method
Subjects
Twenty otherwise healthy male nicotine abstinent
smokers [mean age=32.7 yr ; age range 19–54 and
mean body mass index (BMI)=24.9 ; BMI range
20.2–28.1] were recruited for this study. Subjects were
included in the study if they smoked on average o10
cigarettes per day for at least 1 yr. All participants

M1 receptor modulation of cognition
had no history of psychiatric disorders (as assessed by
the Mini-International Neuropsychiatric Interview),
neurological disorders (including learning disorders),
cardiovascular, liver, respiratory or gastrointestinal
disorders and substance abuse, based on a physical
examination and a clinical and psychiatric interview
by a physician. Subjects were also free of any drugs of
abuse, prescription medication and non-prescription
medications including vitamins, herbal and dietary
supplements. All participants gave written informed
consent for participation in the study, which was approved by the Welwyn Clinical Pharmacology Ethics
Committee, University of Hertfordshire, UK.
Design
The study utilized a randomized, double-blind,
placebo-controlled, cross-over design in which each
participant was tested following three single dose
treatment conditions (placebo, 4 mg GSK1034702 and
8 mg GSK1034702).
Procedure
All subjects underwent screening 30 d before the study
began at the GSK Clinical Unit Cambridge (CUC). In
this screening session, the inclusion and exclusion
criteria described above were applied and the subjects
practised the cognitive assessments (although no data
from these assessments were used in the study analysis). Subjects who satisﬁed screening were then
randomized to placebo, 4 mg GSK1034702 or 8 mg
GSK1034702. The three treatment sessions were separated by a minimum 1 wk washout period. Each
study treatment session was given within a nicotine
abstinence model. In this model, subjects were assessed across two study days (day 1 and day 2).
On day 1, subjects were administered placebo at
approximately 09 : 00 hours and, approximately 5 h
later, baseline cognitive assessments and mood and
craving questionnaire assessments were completed,
while being allowed to smoke cigarettes ad libitum
until midnight (i.e. nicotine ‘ on-state’). Subjects were
housed at the CUC and were escorted by a staﬀ
member to a smoking area. On day 2, pre-drug cognitive testing and questionnaire assessments of mood
and craving were performed in the nicotine ‘abstinent
state’ at approximately 08 : 00 hours. On completion,
subjects were dosed with either placebo or
GSK1034702 and post-dose cognitive testing and
mood/craving measurements were conducted between approximately 5 and 6 h post treatment to
coincide with the time window corresponding to the
highest exposure of GSK1034702 in plasma (2–6 h ;
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tmax ; 2–3 h). Cognitive and questionnaire assessments
were performed approximately 14 h following
nicotine abstinence. In addition to cognitive testing,
electrophysiological recording was conducted between 3 and 4.5 h post treatment and these ﬁndings
are reported elsewhere.
Cognitive assessments
Episodic memory was assessed using the International
Shopping List Test (ISLT). The ISLT is a 12-word, three
trial verbal list learning test. In this task, subjects were
read a list of 12 words. Each word was a concrete noun
and described an item of food commonly eaten. The
experimenter asked the subjects : ‘I am going to read to
you a list of items I want you to get from the supermarket/store/market/shop etc. ’. After the 12 words
were read, the subjects were asked to recall as many of
the words as they could. When they could recall no
more words, the same list was read a second time with
the words in the same order after the same instruction.
This process was repeated three times. At the completion of the computerized battery, subjects were
asked to recall as many of the items as they could from
the shopping list following a delay of 20 min. This
provides a measure of delayed recall. The primary
performance measure from this test is the total number of words recalled across the three learning trials
(total recall) and the total words recalled on the delayed recall trial.
In addition to memory, executive function was
assessed using the Groton maze learning task, psychomotor function was assessed using the CogState
detection task, visual attention was assessed using the
CogState identiﬁcation task and working memory was
assessed using the one back working memory test.
These tests have been described in detail elsewhere
(Fredrickson et al. 2008 ; Thompson et al. 2011).
Mood and craving assessments
Changes in mood were examined using the Visual
Analogue Mood Scales (VAMS) (Bond & Lader, 1974).
The VAMS consist of 16 bipolar scales, anchored at
each end of a 100 mm line. Subjects placed a mark on
each line that best described their current mood state.
The scales were reduced to three subscales to assess
alertness, contentedness and calmness. Nicotine withdrawal was assessed using the Minnesota Nicotine
Withdrawal Scale – Revised (MNWS-R; Hughes &
Hatsukami, 2005). The MNWS-R is a shorter version of
the Minnesota Nicotine Withdrawal Scale, consisting
of a self-report scale divided into seven items, each
representing a speciﬁc state of the nicotine withdrawal
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Table 1. Treatment-related adverse eﬀects
Placebo, N=21

4 mg, N=21

8 mg, N=22

Most frequent AEs

n ( %)

n ( %)

n ( %)

Any AE
Any AE related to investigational product
Gastrointestinal
Any event
Salivary hypersecretion
Abdominal pain
Nausea
Flatulence

7 (33)
2 (10)

8 (38)
4 (19)

14 (64)
12 (55)

0
0
0
0
0

2 (10)
1 (5)
1 (5)
0
0

4 (18)
3 (14)
0
1 (5)
1 (5)

0
3 (14)
1 (5)
0
0
0
0

2 (10)
2 (10)
2 (10)
0
0
0
0

4 (18)
3 (14)
1 (5)
3 (14)
2 (9)
1 (5)
1 (5)

Non-gastrointestinal
Any event
Headache
Fatigue
Hyperhidrosis
Feeling of body temperature changes
Lacrimation
Flushing
AE, Adverse event.

syndrome (e.g. restlessness, desire to smoke, irritability).
Safety and tolerability
The following safety and tolerability endpoints were
monitored : adverse events (AEs) ; 12-lead electrocardiogram (ECG) ; Holter monitoring ; vital signs (blood
pressure, heart rate, respiration rate and body temperature) ; clinical laboratory evaluations (haematology, clinical chemistry, urinalysis and spirometry).

though multiple outcome measures were used, performance on cognitive tests is highly correlated and
therefore corrections that assume independence are
too conservative ; (b) the current study is one of the
ﬁrst of its kind and therefore we consider the outcomes
to be hypothesis generating ; (c) measures of eﬀect size
were computed for all comparisons and eﬀects that
were trivial in magnitude (d<0.2) were not interpreted
irrespective of statistical signiﬁcance. Conﬁdence intervals (CI) are shown, where ‘0 ’ represents no eﬀect,
as well as p values and Cohen’s ‘ d ’.

Pharmacokinetics
Blood samples were collected at regular intervals for
pharmacokinetic analysis.
Statistics
The eﬀects of abstinence on each cognitive task were
examined using a mixed eﬀect analysis of covariance
(ANCOVA) model with subject as a random eﬀect and
period (i.e. day) as a ﬁxed eﬀect. Treatment comparisons for each cognitive task were examined using a
mixed eﬀect ANCOVA model, with subject as a random eﬀect, period and treatment as ﬁxed eﬀects and
baseline as a covariate. For all comparisons, the level of
probability required for signiﬁcance was set at 0.05.
The signiﬁcance level at which each of the comparisons was tested was at the 5 % level. No adjustments
for multiplication were performed because : (a) even

Results
Safety and tolerability
GSK1034702 was well tolerated. The majority of AEs
thought to be related to GSK1034702 were rated as
mild severity, indicating no eﬀect on routine activities
of daily living. No subjects were withdrawn due to
drug-related AEs. Although numbers in this study
were small, muscarinic side-eﬀects appeared to be
dose-related with only gastrointestinal symptoms
(salivary hypersecretion, abdominal pain and diarrhoea) reported at the 4 mg dose and non-gastrointestinal symptoms (headache, dizziness, lacrimination,
ﬂushing, hyperhidrosis and body temperature
changes) appearing at the 8 mg dose. Gastrointestinal
AEs were reported by 10 % of subjects at the 4 mg dose
and by 18 % at the 8 mg dose (see Table 1).

M1 receptor modulation of cognition

Cognitive function
The eﬀect of nicotine abstinence on cognitive function
Nicotine abstinence signiﬁcantly reduced performance on the immediate (d=0.63 ; 95 % CI x1.13 to
x0.0.11 ; p=0.02) and delayed (d=0.62 ; 95 % CI x1.14
to x0.0.11 ; p=0.02) recall trials of the ISLT compared
to the nicotine on-state. No statistically signiﬁcant
eﬀects of nicotine were observed for the detection
(d=0.16), identiﬁcation (d=0.07), one back working
memory (d=x0.07) and Groton maze learning test
(d=0.16).
Eﬀect of GSK1034702 on cognitive function in the nicotine
abstinence model
It was found that 8 mg GSK1034702 signiﬁcantly improved immediate recall in the ISLT (i.e. number of
correct responses ; 95 % CI 0.16–1.38 ; p=0.014) compared to placebo (Figs. 1 and 2), but had no eﬀect on
delayed recall. GSK1034702 (4 and 8 mg) had no
signiﬁcant eﬀects on any of the other cognitive tasks
(Fig. 2 and Table 2).
Mood and craving
No signiﬁcant diﬀerences were noted between the
three treatments for the VAMS alertness, calmness and
contentedness factors or withdrawal symptoms measured by the MNWS-R. However, subjects reported a
greater desire or craving to smoke (95 % CI 0.54–1.71 ;
p=0.0007) and overall had greater withdrawal symptoms (i.e. MNWS-R total score ; 95 % CI 0.39–3.32 ;
p=0.0154) under all treatment conditions in the nicotine ‘ abstinent state ’ compared to the nicotine ‘onstate’.

Baseline (on state)
Pre-dose (abstinence state)
Post-dose (abstinence state)

Number of correct responses

(a)
30
25
20
15
10

Placebo

GSK1034702
(4 mg)

GSK1034702
(8 mg)

Treatment
(b)
Number of correct responses

No clinically signiﬁcant abnormal ECG ﬁndings or
Holter interpretations were reported during the study.
No corrected QT (QTc) values >480 ms were reported
although two subjects (one each in the 4 and 8 mg
treatment groups) had QTcB changes from baseline,
which were >30 to f60 ms. Two subjects had vital
signs of potential clinical importance without any
symptoms. One subject had low diastolic blood
pressure (44 mmHg) recorded during treatment with
placebo and another had low diastolic blood pressure
(44 mmHg) during treatment with 8 mg GSK1034702.
Both subjects had low baseline diastolic blood pressure so these values were considered normal. No abnormal respiration or temperature changes were
reported. The clinical laboratory ﬁndings showed no
clinically signiﬁcant abnormalities.
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Baseline (on state)
Pre-dose (abstinence state)
Post-dose (abstinence state)

10
8
6
4
2

Placebo

GSK1034702
(4 mg)

GSK1034702
(8 mg)

Treatment
Fig. 1. International shopping list task. (a) Immediate recall ;
(b) delayed recall. *p<0.05 for diﬀerence between nicotine
‘ on-state ’ and nicotine ‘abstinent state’. **p<0.05 for
treatment diﬀerence in the nicotine ‘ abstinent state’. Data
expressed as means¡S.E.M.

Pharmacokinetics
Following oral administration of 4 and 8 mg
GSK1034702, the mean tmax was observed 2.3–3.5 h
after dosing, with individual tmax values ranging from
1 to 6 h after dosing.
Discussion
The paucity of selective agonists and antagonists for
cholinergic muscarinic receptor subtypes has been a
major obstacle in elucidating the precise role of these
receptors in modulating cognitive processes. In this
study, we examined the eﬀects of GSK1034702, a
potent M1 receptor allosteric agonist, on cognitive
function in abstinent smokers. The key ﬁnding of the
study was that the M1 allosteric agonist GSK1034702
attenuated the abstinence-induced impairments in
episodic memory (immediate recall) but had no eﬀect
on ‘ baseline’ cognitive function.
Data that support the argument that the eﬀect of
GSK1034702 on episodic memory reﬂects selective
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GSK101034702 4 mg–Placebo
GSK101034702 8 mg–Placebo
GSK101034702 8 mg–GSK101034702 4 mg

Effect size

1.0

0.5

0.0

–0.5

–1.0
Detection
task

Groton maze
test

Identification
task

Shopping list
recall

Shopping list
task

One back
memory

Cogstate test
Fig. 2. Eﬀect sizes for treatment-related diﬀerences (change from baseline) in task performance. Zero value indicates no change.
Note : Shopping list recall (delayed recall), shopping list task (immediate recall).

activation of the muscarinic M1 receptor stem from the
pharmacology of GSK1034702. When tested at human
recombinant M1 receptors in the ﬂuorometric imaging
plate reader (FLIPR) assay, which measures Ca2+
mobilization, an isomer of GSK1034702 (i.e. compound 5) showed potent M1 agonist activity
(pEC50=8.1) and good selectivity against all four receptor human muscarinic receptor subtypes (>100
fold selective for hM1 over hM2-M5 ; Budzik et al. 2010).
Similarly, GSK1034702 was a potent agonist at hM1
receptors (pEC50=8.1) and displayed at least 100-fold
selectivity over hM2–5 receptors. GSK1034702 also
demonstrated partial agonist activity (intrinsic activity
y0.6) at rat, marmoset and human native tissue M1
receptors in a guanosine 5k-O-[c-thio]triphosphate
([35S]GTPcS) binding assay as previously described
(Salah-Uddin et al. 2008). The agonist activity of
GSK1034702 was maintained in post-mortem human
cortex from controls and AD patients, as measured
using [35S]GTPcS binding (pEC50 values of 7.0 in control tissue and 7.5 and 7.0 in mild and severe disease
tissue samples, respectively).
Site-directed mutagenesis of key amino acid residues on hM1 receptors and the FLIPR assay were
also used to establish whether GSK1034702 activates
hM1 receptors through a site distinct to that of the
orthosteric site agonist acetylcholine (ACh). The
potency of ACh to activate the hM1 receptor mutated
at the orthosteric site (Tyr381Ala ; Y381A) was 1000-fold
lower than its potency to activate the wild-type

receptor. In contrast, the potency of GSK1034702 was
not signiﬁcantly aﬀected by this point mutation (pEC50
values of 7.5 and 7.7, respectively). Another mutation
in the orthosteric binding site, Asn382Ala (N382A), also
reduced the potency of Ach (>30-fold), as compared
to wild-type but did not signiﬁcantly aﬀect that of
GSK1034702 (pEC50 values of 7.2 and 7.7, respectively).
In contrast, a mutation in transmembrane domain 2
(Phe77Ile ; F77I) signiﬁcantly reduced the potency of
GSK1034702 (pEC50 values of 6.8 vs. 7.7) without
altering the potency of Ach (see Supplementary
Material and Supplementary Table S1). These data
suggest that GSK1034702 functions through a site on
the hM1 receptor that is distinct to that of ACh.
Overnight nicotine abstinence was associated with a
selective impairment in episodic memory (immediate
and delayed recall) as measured with the CogState
ISLT. No impairments were observed on other cognitive tasks probing attention, working memory and
executive function. The failure to impair other cognitive domains may be related to the study sample (i.e.
smokers who smoked o10 cigarettes per day for at
least 12 months). Previous studies have reported
abstinence-induced impairments in other domains,
including attention, working memory and executive
function, in heavier smokers (i.e. smokers who
smoked o15 cigarettes per day for 12 months ; Myers
et al. 2008). While the present study comprised lighter
smokers, they reported greater desire or craving to
smoke and overall reported more withdrawal
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Table 2. Treatment-related diﬀerences in cognitive performance in the nicotine ‘ abstinent state’
Comparison

Eﬀect size (Cohen’s d)

LS mean test

LS mean reference

Detection task : speed of performance
4 mg – PBO
x0.32
2.46
2.46
8 mg – PBO
x0.12
2.46
2.46
8 mg – 4 mg
0.19
2.46
2.45
Groton maze learning test : total error rate
4 mg – PBO
0.11
37.5
36.34
8 mg – PBO
0.06
37.0
36.34
8 mg – 4 mg
x0.05
37.0
37.49
Identiﬁcation task : speed of performance
4 mg – PBO
0.25
2.65
2.64
8 mg – PBO
x0.12
2.64
2.64
8 mg – 4 mg
x0.37
2.64
2.65
International shopping list recall (delayed recall) : number of correct responses
4 mg – PBO
x0.24
8.29
8.73
8 mg – PBO
0.11
8.93
8.73
8 mg – 4 mg
0.35
8.93
8.29
International Shopping List Task (immediate recall) : number of correct responses
4 mg – PBO
0.30
26.75
25.85
8 mg – PBO
0.77
28.14
25.85
8 mg – 4 mg
0.47
28.14
26.75
One back memory task : accuracy of performance
4 mg – PBO
0.40
1.46
1.42
8 mg – PBO
0.05
1.42
1.42
8 mg – 4 mg
x0.35
1.42
1.46

95 % CI

p value

S.D.

x0.93 to 0.30
x0.71 to 0.47
x0.38 to 0.77

0.31
0.68
0.50

0.03

x0.46 to 0.68
x0.50 to 0.63
x0.61 to 0.52

0.69
0.82
0.87

10.45

x0.28 to 0.78
x0.66 to 0.41
x0.91 to 0.17

0.34
0.64
0.17

0.04

x0.78 to 0.29
x0.41 to 0.63
x0.16 to 0.87

0.36
0.67
0.17

1.80

x0.32 to 0.92
0.16–1.38
x0.14 to 1.08

0.33
0.01
0.13

2.97

x0.15 to 0.97
x0.50 to 0.61
x0.91 to 0.20

0.15
0.85
0.21

0.11

PBO, Placebo.
Data show treatment related change from pre-dose baseline. Summary statistics are reported [eﬀect size, least square (LS) mean,
overall between-subject S.D., 95 % conﬁdence intervals (CI) and p value].

symptoms following nicotine abstinence suggesting
that the overnight nicotine abstinence induced the
desired physiological eﬀect. Alternatively, it is possible that the discrepancy between the current study
and the study by Myers et al. (2008) could be explained
by other factors, such as sample size and the type of
cognitive tasks. The latter study had a slightly larger
sample size (n=25) and included diﬀerent cognitive
tasks to probe attention (continuous performance
task), working memory (2-back) and executive function (arithmetic test). It is possible that these tasks
were more demanding and hence more susceptible to
abstinence induced impairment.
Animal studies have provided insights into the
precise role of M1 receptors on cognitive function.
Studies using muscarinic M1 receptor knockout mice
have suggested that M1 receptors are not essential for
memory formation or initial stability of memory in the
hippocampus. For example, Miyakawa et al. (2001) did
not observe global impairments in hippocampusdependent cognitive tasks probing spatial reference
memory (Morris water maze) or fear learning

(contextual fear conditioning). Slight impairments
were noted in auditory-cued fear conditioning and
working memory measured using the eight-arm radial
maze, but these were thought to be caused by the hyperactivity phenotype observed in the M1 receptor
knockout mice (Miyakawa et al. 2001). A subsequent
study also reported no global impairments in hippocampus-dependent cognitive tasks but, rather, selective deﬁcits on tasks requiring interaction between the
hippocampus and cortex (Anagnostaras et al. 2003).
Speciﬁcally, M1 receptor mutant mice showed impairments in non-matching to sample tasks probing
working memory and consolidation (win-shift radial
arm and social discrimination learning), while having
no eﬀects or improving performance on matching to
sample tasks probing learning (i.e. contextual fear
conditioning and Morris water maze). These ﬁndings
have been interpreted in the context of network models describing cholinergic function in memory processing (Buzsaki, 1989 ; Hasselmo, 1999). According to
these models, cholinergic signals function as a switch
between inﬂow (i.e. encoding) and outﬂow (recall)
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modes of the hippocampus with M1 receptor stimulation hypothesized to bias processing away from the
hippocampus and to the cortex (Anagnostaras et al.
2003). The authors argued that this model may explain
the deﬁcit in cortex dependent working memory and
consolidation of remote memories because the loss of
M1 receptors in the mutant mice would bias processing away from the cortex (Anagnostaras et al. 2003).
They also reasoned that the model could explain the
enhancement in acquisition of contextual memories in
the M1 mutant mice because processing bias would be
shifted to the hippocampus processing contextual
memory without interference from previously established cortical traces (Hasselmo, 1999).
The ﬁndings observed in M1 mutant mice are however inconsistent with pre-clinical studies that have
examined hippocampal activity and nature of cognitive improvement following in vivo administration of
selective M1 receptor agonists. For example, the M1
receptor allosteric agonist and isomer of GSK1034702
(i.e. compound 5 in the N-substituted benzimidazolone series ; Budzik et al. 2010) was shown to enhance
cell ﬁring in the CA1 region of the hippocampus.
Similarly, we have shown that GSK1034702 caused a
signiﬁcant increase of hippocampal CA1 neuronal
ﬁring rate, which persisted following repeated treatment (7 d). In support of the latter studies showing
modulation of hippocampal activity, the selective M1
receptor allosteric agonist, AC-260584, has been
shown to improve spatial memory in a hippocampusdependent Morris water maze task (Vanover et al.
2008) and visual recognition memory in the novel object recognition memory task of working memory
(Bradley et al. 2010) that is reliant on the integrity of
both the cortex (perirhinal cortex) and hippocampus.
Similarly, compound 5 described above (Budzik et al.
2010) and GSK1034702 reversed the scopolamineinduced amnesia in the hippocampus dependent
passive avoidance task of learning. The ﬁndings of the
current study showing improvements in hippocampal
dependent encoding of episodic memory with
GSK1034702 in humans are consistent with the latter
studies in animals. Overall, both pre-clinical and
clinical studies using selective M1 receptor agonists
suggest that M1 receptors are important for hippocampus dependent memory formation. These ﬁndings
do not support the model proposed by Anagnostaras
et al. (2003) based on their work with M1 receptor
mutant mice, suggesting M1 receptor stimulation
would bias processing away from the hippocampus
and to the cortex (Anagnostaras et al. 2003).
Cholinergic innervation of the hippocampus and
muscarinic M1 receptors is critical for the encoding

of episodic memories (Hasselmo & Sarter, 2011). In
rodents, local infusion of scopolamine into the
hippocampus has been shown to impair encoding of
spatial information (Blokland et al. 1992 ; Rogers &
Kesner, 2003). In humans, muscarinic receptor antagonists such as scopolamine have been shown to
impair encoding of stimuli for subsequent free recall
and cued recall (Atri et al. 2004 ; Ellis et al. 2006 ;
Ghoneim & Mewaldt, 1975, 1977 ; Petersen, 1977).
Herein, we report that selectively activating M1 receptors with GSK1034702 improved acquisition or
encoding of new memories as shown by an improvement in learning in the immediate recall task. This
is consistent with pre-clinical studies in rodents
showing improvements in learning and memory
with the selective M1 receptor allosteric agonist,
AC-260584 (Bradley et al. 2010 ; Vanover et al. 2008).
Septohippocampal cholinergic pathways have been
shown to excite hippocampal pyramidal neurons (for
a review, see Nicoll, 1985) and this pathway plays a
critical role in memory functions, including encoding
of episodic memories (for reviews, see Blokland, 1996 ;
Hasselmo & Sarter, 2011). Muscarinic receptor activation has also been shown to enhance hippocampal
pyramidal cell spiking response to aﬀerent input (Cole
& Nicoll, 1984 ; Madison & Nicoll, 1984) and physiologically released ACh from cholinergic neurons has
been shown to enhance LTP of excitatory synaptic
transmission in the hippocampus through postsynaptic M1 mAChR activation (Buchanan et al. 2010 ;
Shinoe et al. 2005). Similar enhancement of hippocampal cell ﬁring rate and LTP has also been reported
with the selective allosteric M1 receptor agonists
(Buchanan et al. 2010 ; Budzik et al. 2010). Furthermore,
ACh release in the hippocampus has been shown to
correlate with improved spatial learning performance
in rats (Fadda et al. 2000). Together, these ﬁndings
suggest that the improvements in encoding and
learning following M1 receptor stimulation may be a
consequence of selective enhancement of the responsiveness of the hippocampus to aﬀerent input for encoding and subsequent consolidation via plasticity
mechanisms including induction of LTP.
The eﬀects of GSK1034702 were speciﬁc to episodic
memory encoding, which was impaired following
nicotine abstinence. In contrast, GSK1034702 had no
eﬀects on ‘baseline ’ or ‘ unimpaired ’ cognitive function (i.e. cognitive processes that were not impaired by
nicotine abstinence, including attention, working
memory and executive function). It is possible that
GSK1034702 may have attenuated these latter cognitive processes if they were also ‘ impaired ’. Indeed,
previous studies have shown robust modulation of

M1 receptor modulation of cognition
attention and working memory following muscarinic
receptor antagonism with scopolamine (Ellis &
Nathan, 2006 ; Hasselmo & Sarter, 2011), suggesting
that M1 receptor agonists could have positive eﬀects
on attention and working memory. Further studies
are required to determine if GSK1034702 could attenuate impaired attention, working memory and executive function in other models of cognitive dysfunction
(i.e. scopolamine or sleep deprivation) or patients with
AD or schizophrenia.
Episodic memory deﬁcits are the hallmark of
AD and these deﬁcits are more related to learning
(encoding and storage) of information rather than retrieval. In this study we provide evidence showing
improvements in episodic memory in an experimental
model of cognitive dysfunction. These ﬁndings are
encouraging and suggest that selective M1 agonists
may have eﬃcacy in the treatment of disorders associated with impaired learning and this warrants
further investigation.
Note
For supplementary material accompanying this paper,
visit http ://dx.doi.org/10.1017/S1461145712000752
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